2030 results for 'CD4'
-
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)
Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
What are MHC Class I and II molecules?(Post)What are MHC Class I molecules? The MHC class I is a glycoprotein that is expressed on all nucleated cells of the human body. MHC class I are important in disease defense against viruses, ba
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
T cell Immunophenotyping - A Guide(Post)Immunology · Flow CytometryT Cell Immunophenotyping: Markers, Subsets and Panel DesignImmunophenotyping identifies cell populations by the proteins on their surface. For T cells that means resolving n
T-cell receptor (TCR) signalling(Page) In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing(Post)A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.
Th17 Cell Differentiation: Insights into Immunological Dynamics(Post)Th17 cells, a subset of T helper cells characterized by their production of interleukin-17 (IL-17), play a significant role in the immune system's response to pathogens and in the pathology of au
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Plozalizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c
Featured
Human CAT (Catalase) ELISA Kit (HUFI07676)
Human MICA ELISA Kit (HUFI00015)
Fatty Acid Oxidation (FAO) Assay Kit (BR00001)
Anti-Mouse IFNAR-1 In Vivo Antibody - Low Endotoxin (IVMB0202)
Anti-Mouse CD25 In Vivo Antibody - Low Endotoxin (IVMB0148)
Anti-Mouse NK1.1 In Vivo Antibody - Low Endotoxin (IVMB0100)
Anti-Mouse PD-1 Antibody [RMP1-14] In Vivo-Low Endotoxin (IVMB0037)
LSAMP Rabbit Polyclonal Antibody (CAB14248)
MCM4 Rabbit Polyclonal Antibody (CAB13513)
VEGF Rabbit Polyclonal Antibody (CAB12303)
MDA ELISA Kit (UNFI0048)
Dopamine ELISA Kit (UNFI0013)
Serotonin ELISA Kit (UNFI0018)
PGE2 ELISA Kit (UNFI0032)
Human IL-6 ELISA Kit (HUFI00180)